The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
Open accessPublished version of a preprint
Abstract
Vaccine protects against B1.1.7 variant: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B1.1.7 (VOC 202012/01) variant that emerged in late 2020 in the United Kingdom has many changes in the spike protein gene. Three of these are associated with enhanced infectivity and transmissibility, and there are concerns that B.1.1.7 might compromise the effectiveness of the vaccine. Muik et al. compared the neutralization efficacy of sera from 40 subjects immunized with the BioNTech-Pfizer mRNA vaccine BNT162b2 against a pseudovirus bearing the Wuhan reference strain or the lineage B.1.1.7 spike protein (see the Perspective by Altmann et al. ). Serum was derived from 40 subjects in two age groups 21 days after the booster shot. The vaccine remained effective against B.1.1.7 with a slight but significant decrease in neutralization that was more apparent in participants under 55 years of age. Thus, the vaccine provides a significant “cushion” of protection against this variant. Science , this issue p. 1152 ; see also p. 1103
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Together with recent reports of the preserved neutralization of SARS-CoV-2 with key S mutations found in the B.1.1.7 and the B.1.351lineage 39,40 , and neutralization of pseudovirus bearing the full set of mutations of B.1.1.7 S 41 , our data indicate broad BNT162b2-elicited immune recognition 2,13,14 .”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [39]
In the citing paper
“Neutralizing activity of the two mRNA vaccines against the B.1.351 variant has also been observed to be lower, by a factor of 8.6 (mRNA-1273 vaccine [Moderna]) or 6.5 (BNT-162b2 vaccine [Pfizer]) on pseudovirus neutralization assay, than activity against the D614G virus, whereas no difference was evident against the N510Y.V1 (B.1.1.7)–like mutant.19,28,29”
From Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [28]
In the citing paper
“As for the ramifications of our findings for the protective efficacy of current SARS-CoV-2 vaccines, the neutralizing activity of sera from vaccinated individuals against B.1.1.7 is largely intact and no adverse effects on current vaccines are expected (Fig. 4c), consistent with conclusions that were reached by other studies 34,40,41 .”
From Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 (2021) · cites this paper as [41]
In the citing paper
“In general, the impact of B.1.1.7 mutations on neutralizing antibody titers is moderate.15, 16, 17, 18,20,24”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [17]
In the citing paper
“Our finding that entry driven by the S protein of the B.1.1.7 variant can be efficiently inhibited by antibodies induced upon infection and vaccination is in agreement with those of Muik and colleagues, who reported that pseudoparticles bearing the B.1.1.7 S protein are efficiently neutralized by sera from BNT162b2-vaccinated individuals (Muik et al., 2021).”
From SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies (2021) · cites this paper as Muik et al., 2021
In the citing paper
“The Pfizer Cominarty (also termed BNT162b2) vaccine-elicited human sera neutralizes SARS-CoV-2 lineage B.1.1.7 pseudovirus, with slightly reduced titers in some vaccinees, when compared to the Wuhan reference strain 26,27 .”
From Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies (2021) · cites this paper as [26]
In the citing paper
“and to elicit strong antibody responses, effectively neutralizing the parental strain as well as diverse SARS-CoV-2 VOCs (13–15).”
From Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera (2022) · cites this paper as [13]
In the citing paper
“The neutralization activity of sera collected from both mRNA-1273 and BNT162b2 vaccinated individuals was largely preserved against the B.1.1.7 variant relative to prior variants.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Self-citationStarr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956 · cited 1×
“One of these mutations, N501Y, was of particular concern because it is located in the receptor binding site, the spike with this mutation binds more tightly to its cellular receptor, ACE-2 (4); and virus with this mutation has an increased host range that includes mice (5).”
BackgroundMapping the Antigenic and Genetic Evolution of Influenza Virus
Smith, D. J., Lapedes, A. S., de Jong, J. C., Bestebroer, T. M., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2004) · Science · doi:10.1126/science.1097211 · Cited by 1,868
Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., O’Toole, Á., et al. (2021) · doi:10.1101/2020.12.30.20249034 · Cited by 1,611 · cited 1×
“7 was detected in the United Kingdom (2), and it subsequently increased in prevalence, showed enhanced transmissibility, and spread to other countries and continents (3).”
BackgroundAssessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England
The COVID-19 Genomics UK (COG-UK) consortium, Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., et al. (2021) · Nature · doi:10.1038/s41586-021-03470-x · Cited by 1,611
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914 · cited 2×
“Further, 19 pseudoviruses, each bearing a SARS-CoV-2 S with a different mutation found in circulating strains, were also neutralized as efficiently as nonmutant SARS-CoV-2 S bearing pseudoviruses by BNT162b2-immune sera (7).”
BackgroundMethodSelf-citationAdaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy
Gu, H., Chen, Q., Yang, G., He, L., Fan, H., Deng, Y.-Q., Wang, Y., Teng, Y., Zhao, Z., Cui, Y., et al. (2020) · Science · doi:10.1126/science.abc4730 · Cited by 762 · cited 1×
“One of these mutations, N501Y, was of particular concern because it is located in the receptor binding site, the spike with this mutation binds more tightly to its cellular receptor, ACE-2 (4); and virus with this mutation has an increased host range that includes mice (5).”
BackgroundBNT162b vaccines protect rhesus macaques from SARS-CoV-2
Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03275-y · Cited by 694
Self-citationCase, J. B., Rothlauf, P. W., Chen, R. E., Liu, Z., Zhao, H., Kim, A. S., Bloyet, L.-M., Zeng, Q., Tahan, S., Droit, L., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.021 · Cited by 410
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 518
SARS-CoV-2 Entry: At the Crossroads of CD147 and ACE2
Fenizia, C., Galbiati, S., Vanetti, C., Vago, R., Clerici, M., Tacchetti, C., & Daniele, T. (2021) · Cells · doi:10.3390/cells10061434 · Cited by 103
Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape
Bushman, M., Kahn, R. J., Taylor, B. P., Lipsitch, M., & Hanage, W. P. (2021) · Cell · doi:10.1016/j.cell.2021.11.026 · Cited by 93
Chakraborty, C., Bhattacharya, M., & Dhama, K. (2023) · Vaccines · doi:10.3390/vaccines11030682 · Cited by 112
“Some studies reported that VEs of the mRNA-based BioNTech, Pfizer vaccine, and mRNA-Moderna mRNA-1273 against alpha were similar to those against the previous variant [95,96].”
ResultWang, H., Miller, J. A., Verghese, M., Sibai, M., Solis, D., Mfuh, K. O., Jiang, B., Iwai, N., Mar, M., Huang, C., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00859-21 · Cited by 93
Neidleman, J. A., Luo, X., McGregor, M. M., Xie, G., Murray, V., Greene, W. C., Lee, S. A., & Roan, N. R. (2021) · eLife · doi:10.7554/elife.72619 · Cited by 89
Bekliz, M., Adea, K., Vetter, P., Eberhardt, C. S., Hosszu-Fellous, K., Vu, D., Puhach, O., Essaidi-Laziosi, M., Waldvogel‐Abramowski, S., Stephan, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31556-1 · Cited by 86
The success of SARS-CoV-2 vaccines and challenges ahead
Subbarao, K. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.016 · Cited by 92
Population immunity predicts evolutionary trajectories of SARS-CoV-2
Meijers, M., Ruchnewitz, D., Eberhardt, J., Łuksza, M., & Lässig, M. (2023) · Cell · doi:10.1016/j.cell.2023.09.022 · Cited by 102
COVID-19 vaccines for low- and middle-income countries
Choi, E. M. (2021) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/trab045 · Cited by 77
“45 Similarly, the levels of antibody neutralisation towards mutations found in the South African and Brazil VOC are reduced but are still above the threshold of protection.”
BackgroundArieta, C. M., Xie, Y. J., Rothenberg, D., Diao, H., Harjanto, D., Meda, S., Marquart, K., Koenitzer, B., Sciuto, T. E., Lobo, A., et al. (2023) · Cell · doi:10.1016/j.cell.2023.04.007 · Cited by 88
Self-citationNatural killer cell‐mediated ADCC in SARS‐CoV‐2‐infected individuals and vaccine recipients
Hagemann, K., Riecken, K., Jung, J. M., Hildebrandt, H., Menzel, S., Bunders, M. J., Fehse, B., Koch‐Nolte, F., Heinrich, F., Peine, S., et al. (2022) · European Journal of Immunology · doi:10.1002/eji.202149470 · Cited by 76
Status Report on COVID-19 Vaccines Development
Kumar, A., Dowling, W. E., Román, R. G., Chaudhari, A. B., Gurry, C., Le, T. T., Tollefson, S., Clark, C. E., Bernasconi, V., & Kristiansen, P. A. (2021) · Current Infectious Disease Reports · doi:10.1007/s11908-021-00752-3 · Cited by 81
Tackling COVID-19 with neutralizing monoclonal antibodies
Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.07.027 · Cited by 78
“…Cell 184, June 10, 2021 bodies, possibly reducing vaccine effectiveness and the duration of protection (Cele et al., 2021; Chen et al., 2021c; Collier et al., 2021; Kustin et al., 2021; Liu et al., 2021a; McCallum et al., 2021a; Muik et al., 2021; Wang et al., 2021b, 2021c; Wu et al., 2021).”
Rotondo, J. C., Martini, F., Maritati, M., Mazziotta, C., Mauro, G. D., Lanzillotti, C., Barp, N., Gallerani, A., Tognon, M. G., & Contini, C. (2021) · Viruses · doi:10.3390/v13091687 · Cited by 81
CRISPR-Cas12a-Based Detection for the Major SARS-CoV-2 Variants of Concern
Liang, Y., Lin, H., Zou, L., Zhao, J., Li, B., Wang, H., Lu, J., Sun, J., Yang, X., Deng, X., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01017-21 · Cited by 78
Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia
Dashdorj, N., Wirz, O. F., Röltgen, K., Haraguchi, E., Buzzanco, A. S., Sibai, M., Wang, H., Miller, J. A., Solis, D., Sahoo, M. K., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.11.004 · Cited by 76
Advances in the design and development of SARS-CoV-2 vaccines
Peng, X., Cheng, J., Gong, H., Yuan, M.-D., Zhao, X., Li, Z., & Wei, D. (2021) · Military Medical Research · doi:10.1186/s40779-021-00360-1 · Cited by 84
Brown, J. C., Goldhill, D. H., Zhou, J., Peacock, T. P., Frise, R., Goonawardane, N., Baillon, L., Kugathasan, R., Pinto, A., McKay, P. F., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.24.432576 · Cited by 70
Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System
Banoun, H. (2021) · The Nephron journals/Nephron journals · doi:10.1159/000515417 · Cited by 77
Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
Muik, A., Lui, B. G., Bacher, M., Wallisch, A.-K., Toker, A., Finlayson, A., Krüger, K., Ozhelvaci, O., Grikscheit, K., Hoehl, S., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.ade2283 · Cited by 71
Self-citationPreparing for the Coronavirus Disease (COVID-19) Vaccination: Evidence, Plans, and Implications
Jung, J. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e59 · Cited by 74
SARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines
Khan, A., Khan, T., Ali, S., Aftab, S., Wang, Y., Wang, Q., Khan, M., Suleman, M., Ali, S., Heng, W., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112176 · Cited by 75
Moncunill, G., Aguilar, R., Ribes, M., Ortega, N., Rubio, R., Salmerón, G., Molina, M. J., Vidal, M., Barrios, D., Mitchell, R. A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2021.103805 · Cited by 74
Verkhivker, G. M., Agajanian, S., Öztaş, D. Y., & Gupta, G. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00139 · Cited by 62
Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbiditiesPreprint
Yelin, I., Katz, R., Herzel, E., Berman-Zilberstein, T., Ben‐Tov, A., Kuint, J., Gazit, S., Patalon, T., Chodick, G., & Kishony, R. (2021) · medRxiv · doi:10.1101/2021.03.16.21253686 · Cited by 72
Fred, S. M., Kuivanen, S. H., Uğurlu, H., Casarotto, P. C., Levanov, L., Saksela, K., Vapalahti, O., & Ċastrén, E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.755600 · Cited by 67
“Recent in vitro studies reported that some of these vaccines remain effective against the variants carrying a set of mutations (Muik et al., 2021; K. Wu et al., 2021; Xie et al., 2021); however, others have shown decreased effectiveness against these variants, particularly to those carrying the…”
A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs
Bogaert, B., Sauvage, F., Guagliardo, R., Muntean, C., Nguyen, V. P., Pottie, E., Wels, M., Minnaert, A., Rycke, R. M. D., Yang, Q., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.009 · Cited by 69
COVID ‐19: vaccination problems
Brüssow, H. (2021) · Environmental Microbiology · doi:10.1111/1462-2920.15549 · Cited by 69
“Vaccine developers assured that even if an adaptation of the vaccine to a new variant virus strain should become necessary in the future, such an adaptation would be facilitated by the flexibility of mRNA-based vaccine technology (Muik et al., 2021).”
BackgroundMethodInfluentialMolecular basis of cross‐species ACE2 interactions with SARS‐CoV‐2‐like viruses of pangolin origin
Niu, S., Wang, J., Bai, B., Wu, L., Zheng, A., Chen, Q., Du, P., Han, P., Zhang, Y., Jia, Y., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021107786 · Cited by 67
Noori, M., Nejadghaderi, S. A., Arshi, S., Carson‐Chahhoud, K., Ansarin, K., Kolahi, A., & Safiri, S. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2277 · Cited by 64
SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence
Tatsi, E., Filippatos, F., & Michos, A. G. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821002430 · Cited by 68
“7), but with a slight decrease in NAc compared to the wild-type strain first observed in Wuhan [76, 77].”
ResultInfluentialOne year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages
Gónzález‐Candelas, F., Shaw, M., Phan, T. G., Kulkarni‐Kale, U., Paraskevis, D. N., Luciani, F., Kimura, H., & Sironi, M. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104869 · Cited by 65
Funk, C. D., Laferrière, C. A., & Ardakani, A. (2021) · Viruses · doi:10.3390/v13030418 · Cited by 57
Zang, J., Zhu, Y., Zhou, Y., Gu, C., Yi, Y., Wang, S., Xu, S., Hu, G., Du, S., Yin, Y., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00315-9 · Cited by 59
The ins and outs of SARS-CoV-2 variants of concern (VOCs)
Salehi-Vaziri, ., Fazlalipour, M., Khorrami, S. M. S., Azadmanesh, K., Pouriayevali, M. H., Jalali, T., Shoja, Z., & Maleki, A. (2022) · Archives of Virology · doi:10.1007/s00705-022-05365-2 · Cited by 61
“These results are in line with others indicating the comparable neutralization capacity of serum panels obtained from convalescent patients and vaccinated individuals against the Alpha variant [77, 79, 80].”
ResultGraham, M. S., Sudre, C. H., May, A., Antonelli, M., Murray, B. A. K., Varsavsky, T., Kläser, K., Canas, L. S., Molteni, E., Marc Modat, A., et al. (2021) · medRxiv · doi:10.1101/2021.01.28.21250680 · Cited by 63
Insights into SARS-CoV-2’s Mutations for Evading Human Antibodies: Sacrifice and Survival
Luan, B., & Huynh, T. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00311 · Cited by 59
Khan, A., Wei, D., Kousar, K., Abubaker, J. A., Ahmad, S., Ali, J., Al‐Mulla, F., Ali, S. S., Nizam‐Uddin, N., Sayaf, A. M., et al. (2021) · ChemBioChem · doi:10.1002/cbic.202100191 · Cited by 59
Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
Liu, J., Budylowski, P., Samson, R., Griffin, B. D., Babuadze, G., Rathod, B., Colwill, K., Abioye, J. A., Schwartz, J. A., Law, R., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj9815 · Cited by 56
Wilton, T., Bujáki, E., Klapsa, D., Majumdar, M., Zambon, M. C. F. A., Fritzsche, M., Mate, R., & Martín, J. E.-S. (2021) · mSystems · doi:10.1128/msystems.00353-21 · Cited by 55
“and vaccine efficacy [13, 16-20], was not detected in viral genomes from sewage.”
BackgroundInhalable nanocatchers for SARS-CoV-2 inhibition
Zhang, H., Zhu, W., Jin, Q., Pan, F., Zhu, J., Liu, Y., Chen, L., Shen, J., Yang, Y., Chen, Q., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102957118 · Cited by 54
“351) have been proven to be reduced (22, 23).”
BackgroundUnderstanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
Lou, F., Li, M., Pang, Z., Jiang, L., Guan, L., Tian, L., Hu, J., Fan, J., & Fan, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744242 · Cited by 54
“The neutralization ability of the serum inoculated with Pfizer BNT162b2 vaccine against pseudovirus with N501Y was almost the same as that of the pseudovirus without the mutation (20, 68).”
BackgroundResultInfluentialThe way of SARS-CoV-2 vaccine development: success and challenges
Dong, Y., Dai, T., Wang, B., Zhang, L., Zeng, L., Huang, J., Yan, H., Zhang, L., & Zhou, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00796-w · Cited by 53
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery
Han, G., Noh, D., Lee, H., Lee, S., Kim, S., Yoon, H. Y., & Hyeon, L. S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114973 · Cited by 53
The molecular basis for SARS-CoV-2 binding to dog ACE2
Zhang, Z., Zhang, Y., Liu, K., Li, Y., Lu, Q., Wang, Q., Zhang, Y., Wang, L., Liao, H., Zheng, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24326-y · Cited by 52
Nel, A. E., & Miller, J. F. (2021) · ACS Nano · doi:10.1021/acsnano.1c01845 · Cited by 50
Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants
Ghimire, D., Han, Y., & Lu, M. (2022) · Viruses · doi:10.3390/v14061255 · Cited by 44
“Similarly, sera of 40 participants vaccinated with the mRNA-based vaccine BNT162b2 had slightly reduced neutralizing capacity but retained neutralizing titers against the Alpha S variant relative to the Wuhan (D614) strain [67].”
BackgroundDiagnostics and analysis of SARS-CoV-2: current status, recent advances, challenges and perspectives
Dong, T., Wang, M., Liu, J., Ma, P., Pang, S., Liu, W., & Liu, A. (2023) · Chemical Science · doi:10.1039/d2sc06665c · Cited by 50
Li, L., Shi, K., Gu, Y., Xu, Z., Shu, C., Li, D., Sun, J., Cong, M., Li, X., Zhao, X., et al. (2024) · Structure · doi:10.1016/j.str.2024.06.012 · Cited by 49
CVnCoV protects human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
Hoffmann, D., Corleis, B., Rauch, S., Roth, N., Mühe, J., Halwe, N. J., Ulrich, L., Fricke, C., Schön, J., Kraft, A., et al. (2021) · doi:10.1101/2021.03.22.435960 · Cited by 48
Review of Covid-19 vaccine clinical trials - A puzzle with missing pieces
Kwok, H. F. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59170 · Cited by 48
Xu, K., Dai, L., & Gao, G. F. (2021) · International Immunology · doi:10.1093/intimm/dxab061 · Cited by 48
Horiuchi, S., Oishi, K., Carrau, L., Frere, J. J., Møller, R., Panis, M., & tenOever, B. R. (2021) · Science Immunology · doi:10.1126/sciimmunol.abm3131 · Cited by 45
Tragni, V., Preziusi, F., Laera, L., Onofrio, A., Mercurio, I., Todisco, S., Volpicella, M., Grassi, A., & Pierri, C. L. (2022) · The EPMA Journal · doi:10.1007/s13167-021-00267-w · Cited by 49
“…will not dramatically change the virulence of new SARS-CoV-2 VoC, making them still sensitive to the current employed Wuhan SARS-CoV-2 based vaccines [29, 93], although a slightly increased VoC-RBD/ACE2 binding affinity might determine a lower affinity for the vaccine induced antibodies [22–24].”
BackgroundZhou, R., Wang, P., Wong, Y.-C., Xu, H., Lau, S.-Y., Liu, L., Mok, B. W.-Y., Peng, Q., Liu, N., Woo, K. F., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103762 · Cited by 50
Long, S. W., Olsen, R. J., Christensen, P. A., Subedi, S., Olson, R., Davis, J. J., Saavedra, M. O., Yerramilli, P., Pruitt, L., Reppond, K., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.03.004 · Cited by 46
“7 variants in vitro.(48) Additional studies have found that convalescent plasma samples from many patients, and some monoclonal antibody therapies, retain the ability to neutralize B.”
The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus
Kim, Y. J., Jang, U. S., Soh, S. M., Lee, J., & Lee, H.-R. (2021) · Viruses · doi:10.3390/v13040633 · Cited by 48
“351 in South Africa (SA) have raised particular concerns owing to increased prevalence and multiple mutations in the spike protein [9].”
BackgroundRamazzotti, D., Angaroni, F., Maspero, D., Mauri, M., D’Aliberti, D., Fontana, D., Antoniotti, M., Elli, E. M., Graudenzi, A., & Piazza, R. (2022) · Virus Evolution · doi:10.1093/ve/veac026 · Cited by 51
Immunity to SARS-CoV-2: Lessons Learned
FERGIE, J. E., & Srivastava, A. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654165 · Cited by 46
“the reference (Wuhan) strain (80), and showed a 0.”
BackgroundThe Genetic Variant of SARS-CoV-2: Would it matter for Controlling the Devastating Pandemic?
Guo, S., Liu, K., & Zheng, J. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59137 · Cited by 46
“BNT162b2 mRNA Pfizer-BioNTech Equivalent to wild type strain*[69] Two - third reduction*[84]”
BackgroundEarly computational detection of potential high-risk SARS-CoV-2 variants
(2023) · doi:10.1016/j.compbiomed.2023.106618 · Cited by 46
Self-citationBiological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences
Hoteit, R., & Yassine, H. M. (2022) · Vaccines · doi:10.3390/vaccines10060919 · Cited by 47
“5-fold average) when exposed to convalescent sera [148].”
BackgroundMethodProfiles of current COVID-19 vaccines
Heinz, F. X., & Stiasny, K. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01835-w · Cited by 45
“with the Biontech/Pfizer mRNA vaccine [72] and the Moderna mRNA vaccine [73].”
MethodRecommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases
Kronbichler, A., Anders, H., Juarez, G. M. F., Floege, J., Goumenos, D. S., Segelmark, M., Tesař, V., Türkmen, K., van Kooten, C., & Bruchfeld, A. N. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab064 · Cited by 46
Chen, Z., Zhang, Y., Wang, M., Islam, M. S., Liao, P., Hu, Y., & Chen, X. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.73583 · Cited by 42
“Studies showed that the most of vaccines are effective in protection against Alpha variant [21-24].”
BackgroundSARS‐CoV‐2 Omicron and its current known unknowns: A narrative review
Le, T. T. B., Vasanthakumaran, T., Hau, N. T. H., Hung, I., Luu, M. N., Khan, Z. A., An, N. T., Tran, V. P., Lee, W. J., Aziz, J. M. A., et al. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2398 · Cited by 42
Khehra, N., Padda, I., Jaferi, U., Atwal, H., Narain, S., & Parmar, M. S. (2021) · AAPS PharmSciTech · doi:10.1208/s12249-021-02058-y · Cited by 41
Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H
Zeng, C., Evans, J. P., Faraone, J. N., Qu, P., Zheng, Y.-M., Saif, L. J., Oltz, E. M., Lozanski, G., Gumina, R. J., & Liu, S. (2021) · mBio · doi:10.1128/mbio.02510-21 · Cited by 41
Schrörs, B., Riesgo-Ferreiro, P., Sorn, P., Gudimella, R., Bukur, T., Rösler, T., Löwer, M., & Şahin, U. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249254 · Cited by 41
“The occurrence of this lineage questioned the efficacy of current vaccines, but first results showed that it at least unlikely will escape BNT162b-induced protection (Muik et al. 2021).”
ResultSelf-citationCOVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective
Marcelin, J. R., Pettifor, A. E., Janes, H., Brown, E. R., Kublin, J. G., & Stephenson, K. E. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac124 · Cited by 41
“The Alpha variant contained several mutations in the spike protein, which did not confer significant immune evasion of vaccineinduced neutralizing antibody responses as tested in vitro [46, 47].”
BackgroundSARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
Hirsch, C., Park, Y. S., Piechotta, V., Chai, K. L., Estcourt, L. J., Monsef, I., Salomon, S., Wood, E. M., So‐Osman, C., McQuilten, Z., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014945.pub2 · Cited by 41
Evolution of the SARS-CoV-2 genome and emergence of variants of concern
Safari, I., & Elahi, E. (2021) · Archives of Virology · doi:10.1007/s00705-021-05295-5 · Cited by 41
Triveri, A., Serapian, S. A., Marchetti, F., Doria, F., Pavoni, S., Cinquini, F., Moroni, E., Rasola, A., Frigerio, F., & Colombo, G. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00857 · Cited by 38
Yu, X., Wei, D., Xu, W., Liu, C., Guo, W., Li, X., Tan, W., Liu, L., Zhang, X., Qu, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29477-0 · Cited by 38
Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay
López, E., Haycroft, E. R., Adair, A., Mordant, F. L., O’Neill, M. T., Pymm, P., Redmond, S. J., Lee, W. S., Gherardin, N. A., Wheatley, A. K., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150012 · Cited by 38
“7 variant carrying the single RBD N501Y 456 mutation (58).”
BackgroundWang, K., Cao, Y., Zhou, Y., Wu, J., Jia, Z., Hu, Y., Yisimayi, A., Fu, W., Wang, L., Liu, P., et al. (2021) · medRxiv · doi:10.1101/2021.09.02.21261735 · Cited by 40
The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance
Soh, S. M., Kim, Y., Kim, C., Jang, U. S., & Lee, H.-R. (2021) · The Journal of Microbiology · doi:10.1007/s12275-021-1348-5 · Cited by 39
“…sera showing neutralizing activity against the WT S protein after first and second dose of administration, 20 sera showed reduced neutralization titers against B.1.1.7 variant with 3.2-fold and 1.9-fold changes respectively (Polack et al., 2020; Collier et al., 2021; Muik et al., 2021).”
BackgroundInfluentialLu, L., Chu, A. W., Zhang, R., Chan, W.-M., Ip, J. D., Tsoi, H., Chen, L., Cai, J., Lung, D. C., Tam, A. R., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103544 · Cited by 39
“There are con fl icting results from these studies, with some showing slight reduction of antibody titers for B.1.1.7 lineage virus [31,32], while others showed no difference [33].”
InfluentialGeneration of human tonsil epithelial organoids as an ex vivo model for SARS-CoV-2 infection
Kim, H. K., Kim, H., Lee, M. K., Choi, W. H., Jang, Y., Shin, J. S., Park, J.-Y., Bae, D. H., Hyun, S., Kim, K. H., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121460 · Cited by 44
Chirumbolo, S. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26922 · Cited by 38
Law, J. L., Logan, M. R., Joyce, M., Landi, A., Hockman, D. J., Crawford, K., Johnson, J., LaChance, G., Saffran, H. A., Shields, J. A., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.081 · Cited by 41
Mason, T., Whitston, M., Hodgson, J., Watkinson, R., Lau, Y., Abdulrazeg, O., & Sutton, M. (2021) · BMC Medicine · doi:10.1186/s12916-021-02149-4 · Cited by 38
Anderson, R. M., Vegvari, C., Hollingsworth, T. D., Pi, L., Maddren, R., Ng, C. W., & Baggaley, R. F. (2021) · Interface Focus · doi:10.1098/rsfs.2021.0008 · Cited by 38
Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variantPreprint
Reuschl, A., Thorne, L., Zuliani‐Alvarez, L., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.24.427991 · Cited by 38
Negi, S. S., Schein, C. H., & Braun, W. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-04950-4 · Cited by 35
Focosi, D., Tuccori, M., Baj, A., & Maggi, F. (2021) · Viruses · doi:10.3390/v13071211 · Cited by 37
Zhou, J., Xu, W., Liu, Z., Wang, C., Xia, S., Lan, Q., Cai, Y., Su, S., Pu, J., Xing, L., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.07.026 · Cited by 41
“The current COVID-19 pandemic caused by SARS-CoV-2 and its variants has posed a serious threat to the global heath and economy 27,32 e 35 , while future outbreaks of highly pathogenic infectious diseases may be caused by emerging and re-emerging coronaviruses 36 .”
Fenizia, C., Galbiati, S., Vanetti, C., Vago, R., Clerici, M., Tacchetti, C., & Daniele, T. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01504-21 · Cited by 38
A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice
Cao, K., Wang, X., Peng, H., Ding, L., Wang, X., Hu, Y., Dong, L., Yang, T., Hong, X., Xing, M., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01578-21 · Cited by 37
SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodiesPreprint
Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B., Kgagudi, P., Tegally, H., Iranzadeh, A., et al. (2021) · bioRxiv · doi:10.1101/2021.03.06.434193 · Cited by 134
“The 501Y.V1 variant did not show substantially increased resistance to neutralizing antibodies, though the subsequent emergence within this lineage of the E484K mutation suggests immune escape (Muik et al., 2021, Wu et al., 2021, Li et al., 2021, Graham et al., 2021, Wise, 2021).”
Barbeau, D. J., Martin, J. M., Carney, E., Dougherty, E., Doyle, J., Dermody, T. S., Hoberman, A., Williams, J. V., Michaels, M. G., Alcorn, J. F., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00504-x · Cited by 37
Martin, D. P., Weaver, S., Tegally, H., San, E. J., Shank, S. D., Wilkinson, E., Lucaci, A. G., Giandhari, J., Naidoo, S., Pillay, Y., et al. (2021) · PubMed · doi:10.34944/dspace/7022 · Cited by 49
Neutralizing potency of COVID‐19 vaccines against the SARS‐CoV‐2 Omicron (B.1.1.529) variant
Lippi, G., Mattiuzzi, C., & Henry, B. M. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27575 · Cited by 33
Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera
Vidal, S. J., Collier, A.-R. Y., Yu, J., McMahan, K., Tostanoski, L. H., Ventura, J. D., Aïd, M., Peter, L. E., Jacob-Dolan, C., Anioke, T., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00404-21 · Cited by 34
“Finally, mRNA-1273 (18, 19) and BNT162b2 (18, 21) vaccine-induced sera showed ;3-8-fold reductions in crossneutralization of B.1.351.”
InfluentialA SARS‐CoV‐2 Neutralization Assay Using Single Molecule Arrays
Gilboa, T., Cohen, L., Cheng, C., Lazarovits, R., Uwamanzu‐Nna, A., Han, I., Griswold, K., Barry, N., Thompson, D. B., Kohman, R. E., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202110702 · Cited by 34
Rodrigues, K. A., Rodriguez‐Aponte, S. A., Dalvie, N. C., Lee, J. H., Abraham, W. D., Carnathan, D. G., Jimenez, L. E., Ngo, J. T., Chang, J. Y. H., Zhang, Z., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj6538 · Cited by 36
Nesterenko, P. A., McLaughlin, J., Tsai, B. L., Sojo, G. B., Cheng, D., Zhao, D. Y., Mao, Z., Bangayan, N. J., Obusan, M. B., Su, Y., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110167 · Cited by 33
“…multiple mutations in the spike protein and can resist antibody neutralization, creating the possibility that, upon further diversifi-cation, viral variants may escape current vaccine defenses (Hoffmann et al., 2021; Kuzmina et al., 2021; Muik et al., 2021; Planas et al., 2021; Wang et al., 2021).”
Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination
Paniskaki, K., Anft, M., Meister, T. L., Marheinecke, C. S., Pfaender, S., Skrzypczyk, S., Seibert, F. S., Thieme, C. J., Konik, M., Dolff, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.816220 · Cited by 33
Muik, A., Lui, B. G., Bacher, M., Wallisch, A.-K., Toker, A., Cadima-Couto, Í., Güler, A., Mampilli, V., Schmitt, G. J., Mottl, J., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.ade9888 · Cited by 36
“Serum neutralizing activity was tested in a well-characterized pseudovirus neutralization test (pVNT) ( 17 , 21 , 22 ) by determining 50% pseudovirus neutralization (pVN 50 ) geometric mean titers (GMTs) with pseudoviruses bearing the S glycoproteins of the SARS-CoV-2 wild-type strain or Omicron…”
Self-citation
Metadata
- Authors
- Muik, A., Wallisch, A.-K., Sänger, B., Swanson, K. A., Mühl, J., Chen, W., Cai, H., Maurus, D., Sarkar, R., Türeci, Ö., Dormitzer, P. R., & Şahin, U.
- Affiliations
- BioNTech (Germany) (DE)
- Pfizer (United States) (US)
- Johannes Gutenberg University Mainz (DE)
- Corresponding author
- Şahin, Uğur
- ORCID
- Venue
- Science
- Published
- 2021-03-12
- Volume
- 371
- Issue
- 6534
- Pages
- 1152-1153
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7971771
- OpenAlex
- W3123108673
- Semantic Scholar
- a28b6633cf65c49f1251702b8e3e3c1b85e19236
- Cited by
- 515
- References
- 12
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 17 · 2023: 34 · 2022: 152 · 2021: 298
- FWCI
- 39.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- SARS-CoV-2, B.1.1.7 lineage, BNT162b2, mRNA vaccines, neutralizing antibodies, spike protein mutations, vaccine escape, pseudovirus neutralization
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adult, Aged, Antibodies, Viral, China, Female, United Kingdom, Humans, Male, Middle Aged, Neutralization Tests, Young Adult, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
